The role of microparticles in pathomechanisms of diabetic retinopathy – analysis of intercellular communication mechanisms in endothelial aging. Case control study in patients with metabolic syndrome, diabetes type 1 and type 2

Ewa Stępień; Iwona Szuścik; Aleksandra Tokarz; Francisco J. Enguita; Bogdan Solnica; Aleksander Żurakowski; Maciej Małecki

doi:10.20883/medical.e87

Authors

Ewa Stępień Department of Clinical Biochemistry, Medical College, Jagiellonian University, Kraków, Poland Department of Medical Physics, M. Smoluchowski Institute of Physics, Jagiellonian University, Kraków, Poland
Iwona Szuścik Private Ophthalmology Practice OKO-LASER Outpatient Clinic, Kraków, Poland
Aleksandra Tokarz Department of Clinical Biochemistry, Medical College, Jagiellonian University, Kraków, Poland
Francisco J. Enguita Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Portugal
Bogdan Solnica Department of Clinical Biochemistry, Medical College, Jagiellonian University, Kraków, Poland
Aleksander Żurakowski Department of Interventional Cardiology, American Heart of Poland SA, Chrzanów, Poland
Maciej Małecki Department of Metabolic Disease, Medical College, Jagiellonian University, Kraków, Poland

DOI:

https://doi.org/10.20883/medical.e87

Keywords:

microparticles, endothelium, diabetic retinopathy, miRNA, vascular ageing

Abstract

The project is proposed to explain the role of specific circulating microparticles (MPs) as conveyors in trafficking bio-active molecules in type 1 (T1DM) and type 2 (T2DM) diabetic patients with risk of diabetic retinopathy (DR) and in patients with metabolic syndrome (MS). The possible role of miRNAs as modulators of these processes (in switching on/off mechanism on the molecular level) is proposed. An increased number of MPs with respect to glucose concentrations and levels of proangiogenic factors in vivo (patients’ plasma) is expected. The relationship between age of patents and MP content (cell membrane glycoproteins, phosphatidylserine or miRNA profile) is possible. MPs will be obtained from T1DM (n = 30) T2DM (n = 30), MS (n = 30) and controls (n = 30). Retinopathy in diabetic patients will be assessed by imaging method. Biological profile of MPs will be assessed in vitro by means of flow cytometry, molecular biology methods and cell proliferation assays.

Downloads

Download data is not yet available.

References

Kim DK, Lee J, Kim SR, Choi DS, Yoon YJ, Kim JH, et al. EVpedia: A Community Web Portal for Extracellular Vesicles Research. Bioinformatics. 2014 Nov 10. DOI: 10.1093/bioinformatics/btu741.

Stępień E, Targosz-Korecka M. Microparticles in endothelial function. Post Biochem. 2013;59(4):395–404.

Orozco AF, Lewis DE. Flow cytometric analysis of circulating microparticles in plasma. Cytometry A. 2010 Jun;77(6):502-14. DOI: 10.1002/cyto.a.20886.

Stępień E, Kabłak-Ziembicka A, Czyż J, Przewłocki T, Małecki M. Microparticles, not only markers but also a therapeutic target in the early stage of diabetic retinopathy and vascular aging. Expert Opin Ther Targets. 2012 Jul;16(7):677–688.

Nomura S. Dynamic role of microparticles in type 2 diabetes mellitus. Curr Diabetes Rev. 2009 Nov;5(4): 245–251.

Konkolewska M, Kurc S, Stepień E. A thousand words about microparticles in cardiology. Journal of Medical Science. 2014;3(83):189–193.

Endemann DH, Schiffrin EL. Endothelial dysfunction. Journal of the American Society of Nephrology: JASN. 2004 Aug;15(8):1983–1992.

Mezentsev A, Merks RM, O'Riordan E, Chen J, Mendelev N, Goligorsky MS, et al. Endothelial microparticles affect angiogenesis in vitro: role of oxidative stress. Am J Physiol Heart Circ Physiol. 2005 Sep;289(3):H1106–H1114.

Malecki MT, Undas A, Cyganek K, Mirkiewicz-Sieradzka B, Wolkow P, Osmenda G, et al. Plasma asymmetric dimethylarginine (ADMA) is associated with retinopathy in type 2 diabetes. Diabetes Care. 2007 Nov;30(11):2899–2901.

Małecki MT, Osmenda G, Walus-Miarka M, Skupień J, Cyganek K, Mirkiewicz-Sieradzka B, et al. Retinopathy in type 2 diabetes mellitus is associated with increased intima-media thickness and endothelial dysfunction. Eur J Clin Invest. 2008 Dec;38(12):925–930.

Morel O, Jesel L, Freyssinet JM Toti F. Cellular mechanisms underlying the formation of circulating microparticles. Arterioscler Thromb Vasc Biol. 2011 Jan;31(1): 15–26.

Ren J, Zhang J, Xu N, Han G, Geng Q, Song J, et al. Signature of circulating microRNAs as potential biomarkers in vulnerable coronary artery disease. PLoS One. 2013 Dec 5;8(12):e80738.

Jansen F, Yang X, Hoelscher M, Cattelan A, Schmitz T, Proebsting S, et al. Endothelial microparticle-mediated transfer of MicroRNA-126 promotes vascular endothelial cell repair via SPRED1 and is abrogated in glucose-damaged endothelial microparticles. Circulation. 2013 Oct 29;128(18):2026–2038.

Hjortoe GM, Petersen LC, Albrektsen T, Sorensen BB, Norby PL, Mandal SK, et al. Tissue factor-factor VIIa-specific up-regulation of IL-8 expression in MDA-MB-231 cells is mediated by PAR-2 and results in increased cell migration. Blood. 2004 Apr 15;103(8):3029–3037.

Kim HK, Song KS, Chung JH, Lee KR, Lee SN, et al. Platelet microparticles induce angiogenesis in vitro. Br J Haematol. 2004 Feb;124(3):376–384.

Rautou PE, Vion AC, Amabile N, Chironi G, Simon A, Tedgui A, et al. Microparticles, vascular function, and atherothrombosis. Circ Res. 2011 Aug 19;109(5):593–606.

McArthur K, Feng B, Wu Y, Chen S, Chakrabarti S. MicroRNA-200b regulates vascular endothelial growth factor-mediated alterations in diabetic retinopathy. Diabetes. 2011 Apr;60(4): 1314–1323.

Alberti KG, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group. The metabolic syndrome – a new worldwide definition. Lancet. 2005 Sep 24–30;366(9491):1059–1062.